Allogene Therapeutics (ALLO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Sol Strategies has shown operational progress and institutional traction, but remains entirely dependent on volatile Solana ...

Discover the Jio Financial Services Stock Liveblog, your go-to destination for real-time updates and comprehensive analysis ...